The global erythropoietin drugs market is poised for steady growth, driven by rising prevalence of chronic diseases and increasing focus on advanced anemia management. Valued at US$ 9.4 Bn in 2023, the market is projected to reach US$ 14.3 Bn by 2034, expanding at a CAGR of 3.8% during the forecast period. Understanding Erythropoietin Drugs Erythropoietin (EPO) drugs, also known as...